Literature DB >> 15005644

Petasites hybridus (Butterbur root) extract in the treatment of asthma--an open trial.

Ulrich C Danesch1.   

Abstract

The efficacy and tolerability of a butterbur root extract (Petadolex) for the treatment of asthma was analyzed in a prospective, non-randomized, open trial. Subjects included 64 adults and 16 children/adolescents treated for two months with the extract, followed by two months during which the intake of the extract was optional. Concomitant asthma medication was permitted. The number, duration, and severity of asthma attacks decreased, while peak flow, forced expiratory volume (FEV1), and all measured symptoms improved during therapy. In addition, more than 40 percent of patients using asthma medications at baseline reduced intake of these medications by the end of the study. This study suggests the Petasites hybridus extract Petadolex is an effective and safe therapy for the treatment of asthma.

Entities:  

Mesh:

Year:  2004        PMID: 15005644

Source DB:  PubMed          Journal:  Altern Med Rev        ISSN: 1089-5159


  3 in total

1.  Immunomodulatory effects of 1-(6-hydroxy-2-isopropenyl-1-benzofuran-5-yl)-1-ethanone from Petasites hybridus and its synthesized benzoxazepine derivatives.

Authors:  Fatemeh Khaleghi; Ibrahim Jantan; Laily Bin Din; Wan A Yaacob; Mohammad A Khalilzadeh; Syed Nasir Abbas Bukhari
Journal:  J Nat Med       Date:  2013-10-24       Impact factor: 2.343

2.  Therapeutic effects of s-petasin on disease models of asthma and peritonitis.

Authors:  Kyoung-Pil Lee; Saeromi Kang; Min-Soo Noh; Soo-Jin Park; Jung-Min Kim; Hae Young Chung; Nam Kyung Je; Young-Geun Lee; Young-Whan Choi; Dong-Soon Im
Journal:  Biomol Ther (Seoul)       Date:  2015-01-01       Impact factor: 4.634

3.  Butterbur (Petasites hybridus) Extract Ameliorates Hepatic Damage Induced by Ovalbumin in Mice.

Authors:  Rana M Alhusayan; Badr Abdullah Aldahmash; Doaa M El-Nagar; Ahmad Rady; Khalid Elfakki Ibrahim; Saad Alkahtani
Journal:  Oxid Med Cell Longev       Date:  2020-12-15       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.